Floatz logo

ZIPRASIDONE

Schizophrenia, Schizoaffective Disorder

Central Institute of Mental Health, MannheimSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Schizophrenia, Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
Risperdal
Hoffmann-La Roche
Phase 4BBB
Ralmitaront
Hoffmann-La Roche
Phase 2B
Olanzapine
Teva Branded Pharmaceutical Products R&D LLC
Phase 1CC
Topamax
Centre for Addiction and Mental Health
N/AD

Same molecule, other indications

ZIPRASIDONE is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
76 / 100
View asset →
Depression, BipolarDormant
BBB
Indicative ·
73 / 100
View asset →
psychotic disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →